

NCT ID	NCT04110093
Title	Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer
Phase	Phase 1/Phase 2
Date Added	2019-10-01
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Regorafenib and PD-1 inhibitor
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04104776
Title	A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Phase	Phase 1
Date Added	2019-09-26
Location	Georgia, United States Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	CPI-0209, CPI-0209
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04096417
Title	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Phase	Phase 2
Date Added	2019-09-19
Location	Arizona, United States Georgia, United States Minnesota, United States North Carolina, United States Tennessee, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pemigatinib
Tags	MSS/ MMRp
NCT ID	NCT04092673

Title	Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Phase	Phase 1
Date Added	2019-09-17
Location	California, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	eFT226, eFT226
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04085185
Title	A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors
Phase	Phase 1
Date Added	2019-09-11
Location	China
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	IBI110, IBI110+ Sintilimab, IBI110, Sintilimab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04062721
Title	Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
Phase	Phase 1
Date Added	2019-08-20
Location	France
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Chemotherapy, In situ immunotherapy
Tags	MSS/ MMRp
NCT ID	NCT04050709
Title	QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Phase	Phase 1
Date Added	2019-08-08
Location	California, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	PD-L1 t-haNK
Tags	MSS/ MMRp
NCT ID	NCT04046445
Title	Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Phase	Phase 1
Date Added	2019-08-06
Location	Arizona, United States California, United States Colorado, United States New York, United States North Carolina, United States Texas, United States Belgium Germany Switzerland
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ATP128, BI 754091, VSV-GP128
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT04041310
Title	Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2019-08-01
Location	California, United States Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT04017650
Title	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
Phase	Phase 1, Phase 2
Date Added	2019-07-12
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, Nivolumab
Tags	MSS/ MMRp